Last reviewed · How we verify
Regadenoson (Lexiscan)
Regadenoson is a selective adenosine A2A receptor agonist that increases coronary blood flow to induce cardiac stress for diagnostic imaging.
Regadenoson is a selective adenosine A2A receptor agonist that increases coronary blood flow to induce cardiac stress for diagnostic imaging. Used for Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise.
At a glance
| Generic name | Regadenoson (Lexiscan) |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Drug class | Adenosine A2A receptor agonist |
| Target | Adenosine A2A receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Regadenoson binds to adenosine A2A receptors on coronary vascular smooth muscle, causing vasodilation and increased coronary blood flow. This mimics the hemodynamic effects of exercise stress testing without the physical exertion, making it useful for cardiac stress testing in patients unable to exercise. The drug is used as a pharmacologic stress agent during myocardial perfusion imaging to detect coronary artery disease.
Approved indications
- Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise
Common side effects
- Dyspnea
- Chest discomfort
- Headache
- Flushing
- Dizziness
- Palpitations
- Hypotension
Key clinical trials
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study (NA)
- Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System (NA)
- Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy
- Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer
- The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (NA)
- Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET (PHASE2)
- A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients (PHASE1, PHASE2)
- Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regadenoson (Lexiscan) CI brief — competitive landscape report
- Regadenoson (Lexiscan) updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI